ondansetron has been researched along with Delayed Effects, Prenatal Exposure in 7 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Literature is divided regarding the risk of neonatal ventricular septal defect (VSD) associated with first trimester ondansetron use in pregnancy." | 7.96 | Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect. ( Bodnar, LM; Caritis, SN; Garrard, W; Lemon, LS; Marroquin, OC; Platt, RW; Venkataramanan, R, 2020) |
| "Literature is divided regarding the risk of neonatal ventricular septal defect (VSD) associated with first trimester ondansetron use in pregnancy." | 3.96 | Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect. ( Bodnar, LM; Caritis, SN; Garrard, W; Lemon, LS; Marroquin, OC; Platt, RW; Venkataramanan, R, 2020) |
| "The exposed group (n = 143) was comprised of children whose mothers received promethazine or ondansetron during pregnancy." | 3.80 | Antiemetic medications in pregnancy: a prospective investigation of obstetric and neurobehavioral outcomes. ( Dajani, NK; Eswaran, H; Larrimer, MB; Newport, DJ; Siegel, ER; Stowe, ZN, 2014) |
| " The experience with mitoxantrone (MIX) especially in the first trimenon is very limited, until now only one case of a pregnant woman with MS who was exposed to MIX in early pregnancy and delivered a growth restricted but healthy child was published." | 3.77 | A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis. ( Chan, A; Epplen, J; Gold, R; Hellwig, K; Schimrigk, S, 2011) |
| "The role of peripheral 5-HT3 receptors in the nociceptive behavioral response and the effect of the 5-HT3 antagonist ondansetron on indices of acute and tonic pain were investigated in the formalin test in 25- and 90-day-old Wistar male rats." | 3.74 | [Antinociceptive properties of the 5-HT3 receptor antagonist in the model of inflammatory pain in rats of different age with prenatal deficit of serotonine and under stress]. ( Butkevich, IP; Makukhina, GV; Mikhaĭlenko, VA, 2007) |
| "Ondansetron is a 5HT3 receptor antagonist widely used to treat hyperemesis gravidarum, although its safety is still questionable." | 1.91 | Safety evaluation of ondansetron after gestational exposure on male reproductive parameters in rats. ( Aquino, AM; Arena, AC; Jorge, BC; Kassuya, CAL; Manoel, BM; Moreira, SDS; Reis, ACC; Scarano, WR; Stein, J; Valente, LC, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Reis, ACC | 3 |
| Jorge, BC | 3 |
| Stein, J | 3 |
| Moreira, SDS | 3 |
| Manoel, BM | 3 |
| Aquino, AM | 3 |
| Valente, LC | 3 |
| Kassuya, CAL | 3 |
| Scarano, WR | 3 |
| Arena, AC | 3 |
| Lemon, LS | 1 |
| Bodnar, LM | 1 |
| Garrard, W | 1 |
| Venkataramanan, R | 1 |
| Platt, RW | 1 |
| Marroquin, OC | 1 |
| Caritis, SN | 1 |
| Larrimer, MB | 1 |
| Dajani, NK | 1 |
| Siegel, ER | 1 |
| Eswaran, H | 1 |
| Newport, DJ | 1 |
| Stowe, ZN | 1 |
| Kamendi, HW | 1 |
| Cheng, Q | 1 |
| Dergacheva, O | 1 |
| Gorini, C | 1 |
| Jameson, HS | 1 |
| Wang, X | 1 |
| McIntosh, JM | 1 |
| Mendelowitz, D | 1 |
| Hellwig, K | 1 |
| Schimrigk, S | 1 |
| Chan, A | 1 |
| Epplen, J | 1 |
| Gold, R | 1 |
| Butkevich, IP | 1 |
| Mikhaĭlenko, VA | 1 |
| Makukhina, GV | 1 |
| Kwon, P | 1 |
| Lefkowitz, W | 1 |
7 other studies available for ondansetron and Delayed Effects, Prenatal Exposure
| Article | Year |
|---|---|
Safety evaluation of ondansetron after gestational exposure on male reproductive parameters in rats.
Topics: Animals; Body Weight; Female; Humans; Male; Maternal Exposure; Ondansetron; Pregnancy; Prenatal Expo | 2023 |
Safety evaluation of ondansetron after gestational exposure on male reproductive parameters in rats.
Topics: Animals; Body Weight; Female; Humans; Male; Maternal Exposure; Ondansetron; Pregnancy; Prenatal Expo | 2023 |
Safety evaluation of ondansetron after gestational exposure on male reproductive parameters in rats.
Topics: Animals; Body Weight; Female; Humans; Male; Maternal Exposure; Ondansetron; Pregnancy; Prenatal Expo | 2023 |
Safety evaluation of ondansetron after gestational exposure on male reproductive parameters in rats.
Topics: Animals; Body Weight; Female; Humans; Male; Maternal Exposure; Ondansetron; Pregnancy; Prenatal Expo | 2023 |
Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect.
Topics: Female; Heart Septal Defects, Ventricular; Humans; Infant, Newborn; Ondansetron; Pregnancy; Pregnanc | 2020 |
Antiemetic medications in pregnancy: a prospective investigation of obstetric and neurobehavioral outcomes.
Topics: Adult; Antiemetics; Child Development; Female; Humans; Infant, Newborn; Longitudinal Studies; Male; | 2014 |
Abolishment of serotonergic neurotransmission to cardiac vagal neurons during and after hypoxia and hypercapnia with prenatal nicotine exposure.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Action Potentials; Animals; Animals, Newborn; Conotoxins; Dose | 2009 |
A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis.
Topics: Abnormalities, Drug-Induced; Adult; Antiemetics; Antineoplastic Agents; Female; Humans; Infant, Newb | 2011 |
[Antinociceptive properties of the 5-HT3 receptor antagonist in the model of inflammatory pain in rats of different age with prenatal deficit of serotonine and under stress].
Topics: Aging; Analgesics; Animals; Female; Inflammation; Male; Ondansetron; Pain; Phenylalanine; Pregnancy; | 2007 |
Neonatal extrapyramidal movements. Neonatal withdrawal due to maternal citalopram and ondansetron use.
Topics: Adult; Anti-Anxiety Agents; Basal Ganglia Diseases; Citalopram; Female; Humans; Infant, Newborn; Lor | 2008 |